NLRP3 and inflammatory bowel disease: These findings support the notion that PH-CC may improve UC symptoms by regulating the NLRP3/caspase-1 pathway, underscoring its potential as a therapeutic agent for inflammatory bowel diseases (Zhu et al., 2024).